Personality as a Predictor of Disability in Multiple Sclerosis

Alcântara, Isabele Jacot de; Voruz, Philippe; Allali, Gilles; Fragnoli, Chloé; Antoniou, Maria Paraskevi; Lalive, Patrice H.; Péron, Julie Anne

doi:10.1093/arclin/acad010

Cited by 3 publications

(2 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, pwMS exhibit more dysfunctional personality traits, including lower levels of conscientiousness, extraversion, and agreeableness and higher levels of neuroticism. It has been proposed that the presence of personality dysfunctions in pwMS may be affected by other psychological disorders commonly seen in this population, specifically anxiety and depression [ 26 ].…”

Section: Discussionmentioning

confidence: 99%

“…In this regard, our analysis indicated that patients with higher disability were more likely to show neuroticism. Regarding prior studies, it has been determined that disability and physical activity are linked to specific personality traits, particularly neuroticism and extraversion [ 26 , 46 , 47 ]. Furthermore, there is a consistent association between extraversion and both walking performance and muscle strength in adults.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Multiple sclerosis and personality traits: associations with depression and anxiety

Vaheb,

Mokary,

Yazdan Panah

et al. 2024

Eur J Med Res

View full text Add to dashboard Cite

Background Depression and anxiety are commonly observed in people with multiple sclerosis (pwMS). There is a growing body of literature supporting the hypothesis that personality traits can influence the mood disorders. This study aimed to investigate the personality traits and their relationships with depression and anxiety among pwMS. Methods 234 pwMS were involved in this cross-sectional study. Personality traits, depression, and anxiety were assessed using the NEO Five-Factor Inventory (NEO-FFI) and Hospital Anxiety and Depression Scale (HADS), respectively. Pearson's correlation coefficient and generalized linear model were employed to evaluate the relationships between demographic and clinical characteristics, NEO-FFI, and HADS subscales. Results In pwMS, longer disease duration was significantly associated with lower level of conscientiousness (β = − 0.23, p = 0.008) and agreeableness (β = − 0.2, p = 0.01). Moreover, higher expanded disability status scale (EDSS) of pwMS had a significant relationship with higher level of neuroticism (β = 0.89, p = 0.01). Increased level of neuroticism was significantly correlated with lower level of extraversion (r = − 0.28, p < 0.001), openness (r = − 0.37, p < 0.001), agreeableness (r = − 0.31, p < 0.001), and conscientiousness (r = − 0.45, p < 0.001). PwMS with higher level of conscientiousness showed more extraversion (r = 0.23, p < 0.001), openness (r = 0.61, p < 0.001), and agreeableness (r = 0.41, p < 0.001). Elevated level of neuroticism was significantly associated with higher level of anxiety (β = 0.47, p < 0.001) and depression (β = 0.11, p < 0.001) among pwMS. Conclusion The co-occurrence of depression and anxiety is probably associated with neuroticism among pwMS. Additionally, the impact of personality traits extends to influencing key disease aspects such as physical disability and disease duration in MS.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Multiple sclerosis and personality traits: associations with depression and anxiety

Vaheb,

Mokary,

Yazdan Panah

et al. 2024

Eur J Med Res

View full text Add to dashboard Cite

show abstract

Treatment switches of disease-modifying therapies in people with multiple sclerosis: long-term experience from the German MS Registry

Frahm,

Ellenberger,

Stahmann

et al. 2024

Ther Adv Neurol Disord

View full text Add to dashboard Cite

Background: The spectrum of disease-modifying therapies (DMTs) for people with multiple sclerosis (PwMS) has expanded over years, but data on treatment strategies is largely lacking. DMT switches are common clinical practice. Objective: To compare switchers and non-switchers, characterize the first DMT switch and identify reasons and predictors for switching the first DMT. Methods: Data on 2722 PwMS from the German MS Registry were retrospectively analyzed regarding sociodemographic/clinical differences between 1361 switchers (PwMS discontinuing the first DMT) and non-switchers matched according to age, sex, and observation period. Frequencies of first and second DMTs were calculated and switch reasons identified. Predictors for DMT switches were revealed using univariable and multivariable regression models. Results: Switchers and non-switchers differed significantly regarding time to first DMT, education, calendar period of the first DMT start (2014–2017 versus 2018–2021), first DMT class used [mild-to-moderate efficacy (MME) versus high-efficacy (HE) DMT], time on first DMT, and disease activity at first DMT start or cessation/last follow-up. The majority of PwMS started with MME DMTs (77.1%), with the most common being glatiramer acetate, dimethyl/diroximel fumarate, and beta-interferon variants. Switchers changed treatment more often to HE DMTs (39.6%), most commonly sphingosine-1-phosphate receptor modulators, anti-CD20 monoclonal antibodies, and natalizumab. Fewer PwMS switched to MME DMTs (35.9%), with the most common being dimethyl/diroximel fumarate, teriflunomide, or beta-interferon. Among 1045 PwMS with sufficient data (76.8% of 1361 switchers), the most frequent reasons for discontinuing the first DMT were disease activity despite DMT (63.1%), adverse events (17.1%), and patient request (8.3%). Predictors for the first DMT switch were MME DMT as initial treatment [odds ratio (OR) = 2.83 (1.76–4.61), p < 0.001; reference: HE DMT], first DMT initiation between 2014 and 2017 [OR = 11.55 (6.93–19.94), p < 0.001; reference: 2018–2021], and shorter time on first DMT [OR = 0.22 (0.18–0.27), p < 0.001]. Conclusion: The initial use of MME DMTs was among the strongest predictors of DMT discontinuation in a large German retrospective MS cohort, arguing for the need for prospective treatment strategy trials, not only but also on the initial broad use of HE DMTs in PwMS.

show abstract

Etiology and pathogenesis of mental disorders in patients with multiple sclerosis: anxiety, psychotic, and personality disorders, chemical addictions, pathological affect

Zimina,

Gubskaya,

Sinitsyna

et al. 2024

Bulletin of Neurology, Psychiatry and Neurosurgery

View full text Add to dashboard Cite

Multiple sclerosis, being a disabling disease, is associated with an increased risk of comorbid mental disorders among adult patients. This literature review is intended to reflect the general picture of MS comorbidity and the spectrum of anxiet y and psychotic disorders: prevalence, features of clinical manifestations, and risk factors of the occurrence of such syntropy. The volume of literature data on the given topic is limited by cross-sectional studies and individual clinical cases, while longitudinal studies that can predict the likelihood of occurrence, course, and outcome of the disease are limited.

show abstract

Personality as a Predictor of Disability in Multiple Sclerosis

Cited by 3 publications

References 39 publications

Multiple sclerosis and personality traits: associations with depression and anxiety

Multiple sclerosis and personality traits: associations with depression and anxiety

Treatment switches of disease-modifying therapies in people with multiple sclerosis: long-term experience from the German MS Registry

Etiology and pathogenesis of mental disorders in patients with multiple sclerosis: anxiety, psychotic, and personality disorders, chemical addictions, pathological affect

Contact Info

Product

Resources

About